Fifty patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) underwent allogeneic bone marrow transplantation between October 1988 and January 1997. Patients received 8 mg/kg of busulfan (BU) with 120 mg/kg of cyclophosphamide (CY) followed by 10 Gy of total body irradiation (TBI). Twenty consecutive patients with AML in first remission (n = 9) or CML in chronic phase (n = 11) entered the study (group I). Thirty consecutive patients with advanced myeloid malignancies including AML (n = 19) and CML (n = 11) also entered the study (group II). The probability of leukemia-free survival at 5 years was 85% for group I patients and 50% for group II patients. Severe regimen-related toxicities occurred in 16% of patients (two in group I, six in group II). The most common sites affected by severe toxicities were lung (n = 6), liver (n = 2) and heart (n = 2). The relapse rate was higher for patients allografted in advanced stages of disease (0% at 5 years for group I and 28% for group II). These results suggest that BU + CY + TBI is a very effective conditioning regimen in patients with myeloid malignancies. Keywords: bone marrow transplantation; busulfan with cyclophosphamide and total body irradiation (BU + CY + TBI); myeloid leukemia Recurrent malignancy and regimen-related toxicity (RRT) are significant problems for allogeneic bone marrow transplantation in hematologic malignancies.
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1,2 Although cyclophosphamide (CY) with total body irradiation (TBI) has been established as a conditioning regimen, 3 studies combining busulfan (BU) and CY as preparation for marrow grafting in patients with hematologic malignancies have reported outcomes similar to CY and TBI regimens. [4] [5] [6] Since BU has a potent antileukemic effect, a conditioning regimen consisting of BU, CY and TBI was studied in several institutions. In studies reported from Seattle, 7-10 the relapse rate and disease-free survival were not improved in Correspondence: Dr N Hirabayashi, Department of Hematology, Nagoya Daini Red Cross Hospital, 2-9 Myokencho, Showaku, Nagoya 466, Japan Received 30 September 1997; accepted 25 January 1998 the patients with advanced myeloid leukemia who received BU, CY and TBI in doses administered in their study.
In preliminary studies, we have reported low relapse rates and incidence of severe RRT in a small number of patients with advanced myeloid malignancies receiving a conditioning regimen of 8 mg/kg of BU with 120 mg/kg of CY followed by 10 Gy of fractionated TBI. 11, 12 We have subsequently used this conditioning regimen in patients with CML in chronic phase and AML in first remission. This report further describes our experience in evaluating the toxicity and antileukemic effects of BU, CY and TBI as a conditioning regimen in patients with myeloid malignancies.
Patients and methods

Patients
Twenty consecutive patients with de novo acute myeloid leukemia (AML) in first remission (n = 9) or chronic myeloid leukemia (CML) in chronic phase (n = 11) entered into the study between March 1992 and October 1996 (group I). The median interval between diagnosis and BMT in patients with AML in first remission was 12.1 months (range 4.6-17.2) and that with CML in first chronic phase was 7.5 months (range 3.4-89.1). Thirty consecutive patients with advanced myeloid malignancies including AML (n = 19) and CML (n = 11) entered into the study between October 1988 and January 1997 (group II). Informed consent was obtained from all patients or their guardians. Details of these patients are shown in Table 1 . Thirty-one donors were HLA-identical siblings. Three patients with CML (one patient in group I and two in group II) and nine patients with AML (three in group I and six in group II) were transplanted from HLA-matched unrelated donors. Two patients with CML in different groups received allografts from phenotypically HLA-matched parents, one patient with CML in group I, from a one-locus mismatched sibling, three patients with AML in group II, from one-locus mismatched parents, and one patient with CML in group II, from a two-loci mismatched parent.
Conditioning regimen
Conditioning therapy for all patients consisted of BU (8 mg/kg administered orally in eight doses over 2 days), followed by CY (120 mg/kg over 2 days) and then TBI (10 Gy as four fractions for 2 days administered at a dose rate of 6 cGy/min between October 1988 and February 1993 (n = 16) and, at a dose rate of 18 cGy/min since March 1993 (n = 34)).
Marrow transplantation and post-transplant immunosuppression
Day 0 was the day of marrow transplantation. Unmodified donor marrow was infused within 30 h after the last dose of TBI. All patients had central venous catheters and received oral non-absorbable antibiotics and anti-fungal agents from day −14. They were nursed in laminar air-flow rooms during the neutropenic phase and received methotrexate (MTX) and cyclosporine (CsA) as graft-versus-host disease (GVHD) prophylaxis. CsA was given intravenously at a dose of 5 mg/kg/day from day −1 and at a dose of 3 mg/kg/day in two divided doses from day 7. Oral CsA, 6 mg/kg/day, was substituted for intravenous when tolerated. Starting on day 100, oral CsA was tapered by 10% biweekly and discontinued on day 360. MTX was given intravenously at a dose of 15 mg/m 2 on day 1 and of 10 mg/m 2 on day 3, 6 and 11. Acute GVHD (grade II) was treated with 1 mg/kg of prednisolone and high-dose methylprednisolone was used for severe acute GVHD (ϾII).
Toxicity grading
A grading system for evaluating RRT in BMT patients was used. 2 If organ damage was not identified as the result of infection, GVHD or drug therapy, it was assumed to be caused by the conditioning regimen and was graded as such. The highest grade in any single organ system determined the overall grade of regimen-related toxicity.
Analysis of data
Data were analyzed as of 15 September 1997. Survival curves were constructed by the method of Kaplan and Meier and comparisons were made using the generalized Wilcoxon test. The significance of observed differences in proportions was tested using the 2 test or Fisher's exact test.
Results
RRT and GVHD
All patients experienced measurable RRT, with mucositis as the most common toxicity. The sites most frequently involved with grade 3-4 toxicity were lung (n = 6), liver (n = 2) and heart (n = 2). Two of 20 patients in group I had grade 3-4 RRT, while six of 30 patients in group II had grade 3-4 RRT. There were seven deaths (14% of all patients) that could be directly attributed to RRT, representing 38.9% of all deaths (Table 2) .
Marrow engraftment occurred in 50 patients (100%). Acute GVHD grade II-IV occurred in seven patients (two in group I, five in group II). Nine of 44 evaluable patients (20.4%) developed chronic GVHD.
Relapse and nonrelapse mortality
Eight of 30 patients in group II relapsed after transplantation at a median of 280.5 days (range 25-2441), and died. Relapse occurred in two patients who had received allografts in second remission, in a patient in third remission, and in five patients with relapsed AML. No patients with Table 2 Number of patients experiencing different grades of regimenrelated toxicity in each organ CML had recurrence of leukemia on hematologic and cytogenetic examination. The 5-year probability of relapse was 28 Ϯ 9% in group II patients (Figure 1) . None of 20 patients in group I relapsed (P Ͻ 0.05). There were 10 deaths from causes other than relapse of leukemia (three of 20 patients in group I vs seven of 22 patients in group II). A single patient died as a direct consequence of acute GVHD. The probability of nonrelapse mortality is shown in Figure 2 . The causes of death were summarized in Table 3 .
Leukemia-free survival
Five-year actuarial probabilities of leukemia-free survival for the patients were 85 Ϯ 8% in group I and 50 Ϯ 10% in group II (P Ͻ 0.05) (Figure 3 ). 
Discussion
Several studies have demonstrated that the preparative regimen for bone marrow transplantation is a determinant of post-transplant survival, leukemia recurrence and regimenrelated toxicity such as hepatic veno-occlusive disease and interstitial pneumonitis (IP). In this study we used a preparative regimen of BU, CY and TBI in patients with CML in chronic phase or AML in first remission. We observed a 5-year leukemia-free survival of 85%. Five-year leukemia-free survival was 50% in more advanced phase patients. Though the number of patients is too small to make a definitive conclusion, our results are comparable to or better than those of several reports. [13] [14] [15] [16] [17] [18] In the present study, severe regimen-related toxicity occurred in 16% of the patients (two patients in group I, six patients in group II). All patients developed mucositis, although it was only grade 1 or 2. Idiopathic interstitial pneumonitis of grade 4 toxicity occurred in six patients. Hepatic toxicity was seen in six patients, but it was grade 4 in only two cases. One of these patients died of hepatic failure and another of IP. Congestive heart failure of grade 3 toxicity was observed in two patients in group II. One of these patients died of leukemia relapse and the other of IP. There was no significant difference in the incidence of severe RRT between the two groups. Interstitial pneumonitis was observed in five of 16 patients who had been irradiated at a dose rate of 6 cGy/min and in 10 of 34 patients, at a dose rate of 18 cGy/min. Severe pulmonary toxicity developed in two of the former cohort and in four of the latter. The radiation dose rate did not affect the incidence of lung impairment in our study. As expected, a low relapse rate was observed for patients with less advanced disease (0% for group I, 28% for group II) in the present study. The lower relapse rate may underlie the better leukemia-free survival in group I patients, although the incidence of severe RRT was not different between the two groups. In group II, the 5-year relapse rate was 42.1% in patients with advanced AML (n = 19) and 0% in those with advanced CML (n = 11) (P = 0.03). The 5-year nonrelapse mortality was 21.3% in patients with advanced AML and 46.3% in those with advanced CML (P = 0.35). Leukemia-free survival (5 years) was 45.6% in patients with advanced AML (n = 19) and 53.7% in those with advanced CML (n = 11) (P = 0.35). In spite of the significant difference in relapse rate, there was no significant difference in leukemia-free survival between two cohorts. We were not able to make a definitive conclusion about whether the conditioning regimen was more effective in advanced CML. As the relapse rate in this study was comparable or superior to that seen in most studies of BMT in patients with myeloid malignancies, 1, [13] [14] [15] [16] [17] [18] further studies are warranted.
The probability of death from causes other than relapse was 15% in group I and 31% in group II patients in the present study. This difference was not statistically significant. These results were better than those reported by the Seattle group using 7 mg/kg of BU, 50 mg/kg of CY and 12 Gy of TBI in patients with advanced disease, where nonrelapse mortality was greater than 50%, relapse rate was 55% and 3-year leukemia-free survival was 20%. 9 The combination of high dose (120 mg/kg) of cyclophosphamide and low dose (10 Gy) of TBI with busulfan may allow the lower incidence of RRT and the better anti-leukemic effect seen in our study, compared with those reported from Seattle. Regimen-related toxicity and nonrelapse mortality in the present study were equivalent to those of other treatment regimens. [17] [18] [19] [20] [21] This report demonstrates that BU + CY + TBI is an effective conditioning regimen for marrow transplantation in patients with myeloid malignancies. The use of BU + CY + TBI has the advantage of a low relapse rate in early stages of myeloid leukemia and in advanced stage of CML. Further studies are warranted.
